List view / Grid view
20 March 2009 | By
Generating knowledge and insight from complex genomic data sets is always a challenging endeavor. As data collection becomes more routine and less expensive, and the existing body of data expands, getting the most out of genomics experiments requires ever more expertise and insight. Here, we discuss our method of integrating…
7 February 2009 | By
The current cost of developing a new medicine for the treatment of human disease has been estimated at $1 to $2 billion (€750-1.5 million1,2). Given progressive increases in the cost of developing new drugs, pharmaceutical companies are facing significant pressure to streamline discovery methods and increase the translational efficiency of…
29 September 2008 | By
Advances in proteomics have constantly altered our understanding of cell biology and biochemistry by providing new approaches and techniques to identify complex proteomes, protein-protein interactions and post-translational modifications. Additionally, proteomic approaches are believed to have enormous potential for discovery of disease biomarkers that can provide diagnostic, prognostic and therapeutic targets…
29 September 2008 | By
European Pharmaceutical Review invited three individuals to discuss current ideas and issues surrounding biomarkers and their possibilities.
19 March 2008 | By
The impact of biomarker technology and biomarker strategies in pharmaceutical development is still in its infancy; but the impact is already proving significant. Biomarker strategy forms the basis for personalised medicine, the industry/regulatory focus centres on improving the success rate and reducing the high attrition rate often encountered in early…
23 May 2007 | By Professor Stephen R Pennington, Proteome Research Centre, Conway Institute of Biomolecular and Biomedical Sciences, University College Dublin
Until recently the use of proteomics in the biomedical arena has included programmes aimed at the elucidation of cellular responses to extracellular stimuli by known and potential drugs. It has been anticipated that these will lead to the elucidation of the basic mechanisms of cellular responses, potential identification of new…
27 March 2007 | By Claudio Carini, MD,PhD,FRCPath, F. VP of Translational Medicine, MDS Pharma
Biomarkers are useful characteristics to evaluate disease progress and targets of therapeutic agents. They are objectively measured and obtained by non-invasive procedures collecting readily accessible matrixes (Blood, CSF). Biomarkers should be easy to detect, specific and reproducible. Most importantly when detected early in the course of a disease they should…
28 November 2006 | By Irina Antonijevic, Douglas Craig and Christophe Gerald, Lundbeck Research USA, Inc.
Only a few innovations have been made in recent decades with regard to psychiatric, and particularly antidepressant, drugs (Insel et al., 2006) (Figure 1). This conundrum reflects, at least partly, the lack of understanding of the disease biology. This poses a challenge not only to inventive drug development, but also…
22 August 2005 | By Dr Graham R Betton, Senior Principal Scientist, Safety Assessment, AstraZeneca Pharmaceuticals
This article reviews the types of biomarkers currently available and approaches to discovering new biomarkers.
20 May 2005 | By William Carley, Ph.D., Experimental Medicine, Pfizer Global R&D
Biomarker application during drug development is driven by the need to define disease and therapeutic efficacy/safety earlier, better and with reduced cost.
7 March 2005 | By Thorir D. Bjornsson, MD, PhD, Translational Development, Wyeth Research
The past decade has witnessed a growing interest in biomarkers, previously referred to as pharmacodynamic markers, PD markers, or pharmacologic read-outs. This increasing interest has been largely driven by evolutionary changes in drug discovery and development and in regulatory science1,2,3. One key driver has involved the increasing need to reach…
